The Alizé Pharma companies were founded and managed by biotech executives with a sound track record in the biopharmaceutical industry.


Thierry Abribat

Thierry Abribat DVM, PhD

Founder Alizé Pharma

A doctor in Veterinary Medicine and a PhD from the National Polytechnic Institute of Toulouse, Thierry began his career as scientist at Sanofi-Recherche (Toulouse, France), then at University of Montreal and as a consultant to the biopharmaceutical industry. He has then held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TH.TO, Montreal, Canada) and at OPi SA (Lyon, France), until OPi’s acquisition by EUSA Pharma Inc. He is Manager (gérant) at TAB Consulting, the coordinating holding company and President of the Alizé Pharma companies.

Soraya Allas

Soraya Allas MD, PhD

Medical Director Alizé Pharma

Soraya Allas joined Alizé Pharma in June 2008. Soraya holds an M.D. from the University of Algiers and a Ph.D. in biomedical science from the University of Montréal. Over the last 20 years, she has gained international experience in drug development including preclinical and clinical research in a CRO, then at Theratechnologies (TH.TO) as director, Clinical Science and medical director. She was notably involved in the design, implementation and data analysis of Phase I, Phase II and Phase III programs and in interactions with regulatory authorities including FDA, Health Canada and EMEA.

André de Villiers

André de Villers MD, President CEMA Inc.

Member of the Board, Alizé Pharma SAS

Dr. de Villers has been closely involved in the emergence of the biotechnology sector in Quebec. From 1988 to 1993, he created and successfully managed several R&D venture capital companies, generating an investment totaling $250 million. He is the founder of Theratechnologies (TH.TO), which he served as president from 1993 to 2004. From 2004 to 2006, he was chairman of the board and CEO of Celmed Bioscience. Dr de Villers is now the president of CEMA Inc, an independent investment company based in Montreal, Canada.

Gilles Alberici PharmD, PhD, President, initiative Octalfa

Member of the Board, Alizé Pharma SAS and Alizé Pharma III SAS
Gilles Alberici has more than 20 years of experience in the European pharmaceutical industry as a successful entrepreneur. He is a pharmacist and doctor in Immunology. From 1994 to 1999, he founded and directed IMTIX -within Pasteur-Merieux- then IMTIX-SangStat. More recently, from 1999 to 2007, he developed OPi, Pharmaceuticals for rare diseases. Since 2006, Gilles has been managing initiative OCTALFA, a family-owned independent investment company specializing in Life Sciences, and the Dominique & Tom Alberici-OCTALFA Foundation.

Olivier Martinez

Olivier Martinez, PhD, MBA, Investment Director, Bpifrance, Paris

Member of the Board, Alizé Pharma SAS

Olivier Martinez is Investment Director in the Life Sciences Division of Bpifrance which manages the €173m InnoBio Fund. Prior to that, Olivier has been Investment Director within CDC Enterprises (2010-2013) and Partner of Bioam Gestion (2000-2010). Olivier Martinez also sits on the boards of Adocia (ADOC, Euronext), Fab Pharma, Genticel (GTCL, Euronext), Poxel, Innate Pharma (IPH, Euronext), and Cerenis Therapeutics. He is an alumnus of the Ecole Normale Supérieure and holds a PhD in cell biology from the University of Paris XI and a MBA from the Collège des Ingénieurs.

Mounia Chaoui

Mounia Chaoui, General partner, Turenne Capital

Member of the Board, Alizé Pharma SAS and Alizé Pharma III SAS

Mounia Chaoui is General partner at Turenne capital in charge of Venture and Growth Capital in healthcare totaling 110 M€. Prior to this, Mounia has been a Life Science investor within Ventech, Inserm Transfert Initiative and Atlas Venture. She has been on the board of Biovex (sold to Amgen for up to 1B$), Covagen (sold toJ&J), Funxional Therapeutics (sold to Boehringer), Tigenix (now EUR:TIG) and Scynexis (SCYX). Besides Alize Pharma, Mounia sits on the board of Actogenix, Didactic, DNA therapeutics, Eyegate, Eyetechcare, Prosonix, and Sebbin. Mounia has a PhD in Biophysics and an Engineering degree from Ecole Centrale Paris.

François Micheli


Member of the Board, Alizé Pharma III SAS

François Miceli is Senior Partner with SOFIMAC Partners Capital Investment where he is in charge of innovation technology investments since 2009. Prior to that, he has cumulated over 20 years of international experience in the biotech and pharmaceutical industry, with executive positions at Clonatec, Idexx Laboratories, Synbiotics and Imaxio. Besides Alizé Pharma III, François also sits on the boards of Indatech, Vactec, Eydo Pharma, Aptys Pharmaceuticals, Cellmade, Elsalys Biotech, Isorg, Primo 1D, The Cosmo Company, Crossject and Carelabs.


A.J. van der Lely, MD

Co-Founder and Scientific Advisor, Alizé Pharma SAS

Chair, Endocrinology section, Erasmus Medical Center

President of the European Society of Endocrinology

Dr van der Lely is Professor of Clinical Endocrinology. He is currently Vice-Chair, Department of Internal Medicine and Chair of the Endocrinology Section at the Erasmus Medical Center in Rotterdam, The Netherlands. He is the past-president of the Dutch Endocrine Society and the past-secretary of the European Union of Medical Specialists (UEMS), section of endocrinology. He is the past-treasurer and current president of the European Society of Endocrinology. He also served on the Executive Board of the International Society of Endocrinology. His main research areas are pituitary diseases and the role gut hormones in health and disease. He has published more than 200 original papers and book chapters. Dr Van der Lely has also served or is serving as consultant for several pharmaceutical companies including Sensus, Pharmacia, Novartis, Theratechnologies, Pfizer, Ipsen and Human Genome Sciences.

 Ezio Ghigo

Ezio Ghigo, MD

Co-Founder and Scientific Advisor, Alizé Pharma SAS

Head, Endocrinology Department

Dean of the Faculty of Medicine, University of Torino

Dr Ghigo is Professor of Endocrinology and Metabolism, Chairman of the Department of Endocrinology and Dean of the Faculty of Medicine at the University of Turin, Italy.  His research interests include the neural control of anterior pituitary function, ghrelin and synthetic GH secretagogues, the endocrinology of ageing, diabetes, and anorexia nervosa. He has authored or coauthored over 300 papers.  Dr Ghigo has also served or is serving as consultant for several pharmaceutical companies including Pierrel, KabiVitrum, Pharmacia, Europeptides, Schwarz Pharma, Novartis, Theratechnologies, Pfizer, Ipsen.